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Essentials
• CLEC4M is an endocytic receptor for factor FVIII.
• CLEC4M interacts with FVIII in a VWF-dependent and independent manner.
• CLEC4M binds to mannose-containing glycans on FVIII.
• CLEC4M internalization of FVIII involves clathrin coated pits.
Summary. Background: von Willebrand factor (VWF) and factor VIII (FVIII) circulate in the plasma as a non-covalent complex, and the majority of FVIII is likely to be cleared by VWF-dependent pathways. Clearance of VWF-free FVIII is rapid and underlies the pathological basis of some quantitative FVIII deficiencies. The receptor pathways that regulate the clearance of VWF-bound and VWF-free FVIII are incompletely uncharacterized. The human liver-expressed endothelial lectin CLEC4M has been previously characterized as a clearance receptor for VWF, although its influence on FVIII is unknown. Objective: The interaction between FVIII and CLEC4M was characterized in the presence or absence of VWF. Methods: FVIII interactions with CLEC4M were evaluated by in vitro cell-based and solid phase binding assays. Interactions between FVIII and CLEC4M or liver sinusoidal endothelial cells were evaluated in vivo by immunohistochemistry. Results:
CLEC4M-expressing HEK 293 cells bound and internalized recombinant and plasma-derived FVIII through VWF-dependent and independent mechanisms. CLEC4M binding to recombinant FVIII was dependent on mannoseexposed N-linked glycans. CLEC4M mediated FVIII internalization via a clathrin-coated pit-dependent mechanism, resulting in transport of FVIII from early and late endosomes for catabolism by lysosomes. In vivo hepatic expression of CLEC4M after hydrodynamic liver transfer was associated with a decrease in plasma levels of endogenous murine FVIII:C in normal mice, whereas infused recombinant human FVIII was associated with sinusoidal endothelial cells in the presence or absence of VWF. Conclusions:
Introduction
Plasma levels of the glycoprotein coagulation factor VIII (FVIII) are highly variable in the normal population (50-200%). Low levels of FVIII are associated with the inherited bleeding disorders hemophilia A and von Willebrand disease (VWD) (< 1-50%), whereas epidemiological studies and animal models have linked elevated plasma FVIII levels to an increased risk of venous and arterial thrombosis (> 150%) [1] [2] [3] . Plasma FVIII levels are influenced by the rate at which FVIII is synthesized and secreted, its rate of clearance from the plasma, and its interaction with the multimeric glycoprotein von Willebrand factor (VWF). Approximately 95-97% of plasma FVIII circulates in the plasma in a dynamic equilibrium with VWF [4] [5] [6] . VWF protects FVIII from proteolysis [7] , as well as from accelerated clearance from the plasma [8] , and thus the concentration of circulating VWF, and the binding affinity between VWF and FVIII regulate plasma FVIII levels. The majority of circulating FVIII is thus likely to be cleared through VWF-dependent receptor-ligand interactions. However, VWF-independent clearance pathways for FVIII have both physiologic and pathophysiologic relevance. Although the amount of VWF-free FVIII in the circulation is relatively low, it has a 6-8-fold faster clearance rate than VWF-bound FVIII, suggesting that the proportion of FVIII cleared in a VWF-independent manner is thus substantial. Moreover, inherited bleeding disorders involving quantitative FVIII deficiency can result from accelerated clearance of VWF-free FVIII. Type 2N VWD is characterized by pathogenic variants in the D'D3 FVIII-binding region of the VWF gene that result in impaired binding of VWF to FVIII, resulting in isolated FVIII deficiency [9] . Conversely some mild/moderate forms of hemophilia A are the result of F8 gene variants that impair FVIII binding to VWF [10] . In both cases, the pathways that underlie this pathological enhanced clearance of VWF-free FVIII are largely unknown. Furthermore, as elevated plasma FVIII is a risk factor for thrombosis, the rapid clearance of VWFfree FVIII in normal individuals may be crucially important in maintaining physiological FVIII levels, and dysregulation of these clearance pathways could contribute to elevated plasma FVIII levels and an increased risk of thrombosis.
Variants in the VWF gene and the VWF-modifying ABO blood group locus account for approximately 50% of the variability in plasma FVIII levels [11] . As every 1% change in plasma VWF levels is associated with ã 0.54% change in plasma FVIII:C [12] , it is thought that the majority of quantitative trait loci that modify plasma VWF also modify FVIII but with a decreased magnitude of influence and statistical association. Genome-wide association studies (GWAS) analyses have identified variants in genes involved in biosynthesis and secretion and receptor-mediated clearance as associating with both plasma levels of VWF and FVIII [13] [14] [15] . Interestingly, VWF but not FVIII plasma levels were associated with a common variant within the CLEC4M gene (rs868875), which encodes a transmembrane calcium-dependent lectin receptor (encoding CLEC4M [Ctype lectin member 4 family M], also termed L-SIGN or DC-SIGNR) expressed on the sinusoidal endothelial cells of the liver and lymphoid tissues [16] . CLEC4M had been previously described as an adhesive receptor for pathogens such as HIV, capable of mediating infection in trans in an ICAM-3-dependent manner [17] . Importantly, although no association between CLEC4M gene variants and plasma FVIII levels was reported, this may be related to the genome-wide significance cut-off threshold for reporting this association, rather than an absence of a biological interaction between FVIII and CLEC4M.
We and others have previously found that variants within the CLEC4M gene, including the GWAS-identified SNV rs868875, or a variable number of tandem repeat (VNTR) polymorphism in the neck region of CLEC4M, which is in linkage disequilibrium with the rs868875 SNV, can modify the phenotype of type 1 VWD [18, 19] . We have also demonstrated that CLEC4M can bind VWF through interactions with its N-linked glycans, and mediate the internalization of VWF to early endosomes [18] . However, the ability of CLEC4M to interact with FVIII in the presence or absence of VWF has not been characterized. Additionally, the mechanistic basis by which CLEC4M is able to facilitate internalization of its glycoprotein ligands has not been demonstrated. In these studies, we investigate the ability of CLEC4M to act as an endocytic receptor for FVIII in the presence and absence of VWF. We further characterize the mechanism by which CLEC4M binds and internalizes FVIII and describe the subsequent endocytic pathway of this ligand.
Methods and materials

FVIII products
Plasma-derived VWF-FVIII (2.4 : 1, Humate-P) was from CSL Behring (King of Prussia, USA) and 1 : 1, Wilate was from Octapharma, Lachen, Switzerland. Human recombinant FVIII (rFVIII) products included Advate (Baxter, Deerfield, IL, USA), Kogenate-FS and Kovaltry (Bayer, Leverkusen, Germany), Xyntha (Pfizer, New York, NY, USA) and Nuwiq (Octapharma). Plasmaderived FVIII (pdFVIII) (Haemocetin) (Biotest, Dreieich, Germay) had been purified to contain 1% VWF. All experiments unless otherwise specified were performed with Advate (rFVIII) or Humate P (pdVWF-FVIII).
Imaging studies
Cell culture. A HEK 293 stable cell line expressing CLEC4M possessing the 7 copy VNTR polymorphic allele and a control (pCIneo stable cells) were generated and maintained as described [18] .
Antibodies. Antibodies used included: sheep anti-FVIII (Affinity Biologicals, Ancaster, Canada), rabbit anti-VWF (Dako, Agilent, Santa Clara, CA, USA), mouse anti-CLEC4M (R&D, Minneapolis, MN, USA), rabbit anti-CLEC4M (Novus, Littleton, CO, USA), rabbit anti-EEA1 (Cell Signaling Technology, Beverly, MA, USA), rabbit anti-Rab9 (Cell Signaling Technology), mouse anti-LAMP1 (Abcam, Cambridge, UK) and rat anti-murine CD31 (Dianova, Hamburg, Germany).
Immunocytochemistry. CLEC4M-expressing cells were exposed to rFVIII or pdVWF-FVIII in binding buffer (10 mM HEPES pH 7.4, 135 mM NaCl, 10 mM KCl, 5 mM CaCl 2 , 2 mM MgSO 4 ) for 15-120 min. Cells were washed and prepared as previously described [18] [20] . Thirty minutes post-infusion, tissues were prepared by saline and formaldehyde perfusion. Immunohistochemistry (IHC) analysis was performed on formalin-fixed paraffin-embedded 7-lM tissue sections as previously described [20] . Imaging was performed using a Leica SP8 laser scanning confocal microscope with 639 oil immersion objective. Images were analyzed using ImageJ or FIJI software (NIH, Bethesda, MD, USA).
Enhanced sensitivity human FVIII:Ag ELISA FVIII ELISA (Affinity Biologicals, Ancaster, Canada) was performed according to the manufacturer's protocols using a biotinylated sheep anti-factor VIII (Affinity Biologicals) antibody followed by incubation with streptavidin poly-HRP (Pierce/Thermo Scientific, Rockford, IL, USA) and developed with o-Phenylenediamine (Sigma Aldrich). To quantify FVIII:Ag in cell lysates, FVIII levels were normalized to total protein concentration (BioRad, Hercules, CA, USA). For some experiments, cells were preincubated with rFVIII for 5 h, followed by incubation with chloroquine disulfide (250 lM) (Sigma Aldrich), MG132 (50 lM in DMSO) (Sigma Aldrich), NH 4 Cl (20 mM) (Sigma Aldrich) or DMSO (0.2%) vehicle control for 2 h prior to lysis.
Solid phase immunosorbent assay
The interaction between FVIII and recombinant CLEC4M-Fc chimera (R&D, Minneapolis, MN, USA) was measured as previously described [18] with several modifications. Maxisorp plates were coated with FVIII (Nunc, Rochester, NY, USA) in 50 mM Na 2 HCO 3 and Fc-chimera binding was detected with an HRP-conjugated goat anti-human Fc antibody (AbCam). Alternatively, CLEC4M-Fc was coated in carbonate buffer and FVIII binding was detected with an anti-FVIII-HRP antibody (Affinity Biologicals) or a monoclonal anti-FVIII A1 antibody 8002 (Green Mountain Antibodies, Burlington, VT, USA) with a goat-anti Mouse Ig-HRP (Southern Biotech, Birmingham, AL, USA). For all experiments, CLEC4M-Fc or FVIII binding was compared with background binding to a bovine serum albumin (BSA)-coated negative control. For some experiments, FVIII and/or Fc chimera proteins were preincubated with 1 mg mL À1 mannan or anti-VWF (Dako), or anti-FVIII polyclonal (Affinity Biologicals) or monoclonal antibodies GMA-8002, -8016, -8011 or -8008 (Green Mountain Antibodies) (100 lg mL
À1
) for 30 min at room temperature. Mannan and a-mannosidase used for some experiments were from Sigma Aldrich.
Animal models
Hepatic expression of CLEC4M in mice was induced via hydrodynamic gene transfer of the CLEC4M cDNA in the pLIVE liver expression vector [18] . FVIII:C was measured using the Chromogenix Coatest assay (Diapharma, West Chester, PA, USA) according to the manufacturer's directions against a normal C56Bl/6 mouse plasma pool. Recombinant human FVIII was administered by tail vein infusion (100 U per mouse) and tissues were perfused with saline and formalin after 30 min. VWF/FVIII DKO mice were generated on a C57BL/6 background [21, 22] . To induce liver sinusoidal endothelial cell (LSEC) cytotoxicity, mice received an intraperitoneal injection of 200 mg kg À1 cyclophosphamide (Sigma Aldrich) 24 h prior to study [23] . Human rFVIII was administered at 200 IU kg À1 by tail vein injection and blood was collected via the retro-orbital plexus into 10% buffered citrate. Samples were centrifuged at 10 0009g for 10 min and maintained at À80°C until FVIII:Ag ELISA.
Statistical analysis
A t-test or one-way ANOVA was performed on experiments with n ≥ 4 using GraphPad Prism software version 7 (La Jolla, CA, USA). Values are expressed as mean AE standard error. The figures denote P < 0.05 with * and P < 0.001 with **.
Results
FVIII and the VWF-FVIII complex are internalized by CLEC4M-expressing cells in vitro
CLEC4M is expressed on the sinusoidal endothelial cells of the liver and lymphoid tissues [16] , which rapidly lose their phenotype in culture [24] and commercially available primary liver or lymphatic sinusoidal endothelial cells do not express CLEC4M (C. Notley & D. Lillicrap, unpublished observations). We therefore generated a stable CLEC4M-expressing HEK 293 cell line that was > 90% CLEC4M-positive [18] . CLEC4M-expressing and pCIneo (stable vector backbone) control cells were exposed to FVIII products at physiological concentrations [25] .
Immunofluorescence demonstrated that rFVIII, pdFVIII and the pdVWF-FVIII complex were internalized by CLEC4M-expressing cells after 1 h (Fig. 1A-C) , and not by control cells that did not express CLEC4M (Figure S1D and E). FVIII colocalized with CLEC4M in cells exposed to rFVIII (Fig. 1A) , pdFVIII (Fig. 1B) or the VWF-FVIII complex (overlay not shown). Additionally, we observed that on CLEC4M-expressing cells exposed to the VWF-FVIII complex, VWF and FVIII partially colocalized ( Fig. 1C) , suggesting that CLEC4M can also bind and internalize VWF and FVIII as a complex. For all imaging conditions, CLEC4M-negative and isotype controls were performed ( Figure S1 ). The binding and internalization of rFVIII ( Fig. 1D and E) or pdVWF-FVIII ( Fig. 1F and G) by CLEC4M-expressing cells were quantified. Cells were exposed to physiological or therapeutic FVIII concentrations as described, and cells were washed and lysed and FVIII:Ag in cell lysates measured using an enhanced sensitivity ELISA. Cells expressing CLEC4M had approximately 2-fold more FVIII detected in cell lysates than cells that did not express CLEC4M, suggesting that CLEC4M is able to bind and/or internalize FVIII alone or as part of a complex with VWF. FVIII observed in the lysate of cells that did not express CLEC4M may be bound to the HEK 293 cell surface via FVIII C2 domain interactions with the phospholipid membranes, or by heparan sulfate proteoglycans. It is currently unknown if these interactions enhance the capture and endocytosis of FVIII by endocytic receptors such as CLEC4M, as previous reports have also indicated that FVIII interactions with heparan sulfate proteoglycans on the cell surface can enhance the internalization by LRP1 [26] .
We observed a difference in the total amount of FVIII internalized between the two products. As the ratio of VWF to FVIII in the plasma-derived complex is 2.4 : 1, FVIII only accounts for a fraction of the total material internalized, and the relative size of the VWF-FVIII complex is much larger than rFVIII alone, which may alter the rate of internalization. Additionally, rFVIII (VWFfree) was used as a standard for both assays, as internalized FVIII is rapidly denatured and degraded, and thus may lose its VWF-binding ability. However, the presence of some VWF-bound FVIII in these lysates may decrease the apparent amount of FVIII detected by the polyclonal anti-FVIII antibody ( Figure S5 ).
CLEC4M binds mannose-exposed glycans on FVIII
We next confirmed that CLEC4M interacts with FVIII using a solid phase binding assay with recombinant CLEC4M-Fc fusion protein in a dose-dependent manner; assuming the specific activity of this product is 1 IU = 100 ng mL À1 [27] , this interaction has an apparent Kd of < 0.1 nM ( Fig. 2A and B) . We further demonstrated that binding to rFVIII occurred in a plasma environment AE VWF (Fig. 2C) , was calcium dependent and reversible and could be partially blocked by preincubation with the mannose polymer mannan or with soluble pdVWF-FVIII or rFVIII (Fig. 2D) . Immobilized CLEC4M-Fc bound to second and third-generation rFVIII products (Fig. 2E) , and pdFVIII (< 1% VWF) and pdVWF-FVIII complex (Fig. 2G) . Of note, differences in the interaction between FVIII products may be related to glycan content or specific activity of each product, and the variable recognition of FVIII (AE VWF) products by the polyclonal anti-FVIII detection antibody ( Figure S5 ). Preincubation of immobilized FVIII with monoclonal antibodies to the A2, C1 and C2 domains (Fig. 2E ) could partially attenuate binding to CLEC4M-Fc. Preincubation of Humate P with a polyclonal anti-VWF antibody (Affinity Biologicals) attenuated binding to CLEC4M-Fc, whereas an anti-FVIII antibody did not (Fig. 2H) .
We have previously demonstrated that CLEC4M-Fc interacts with N-linked glycans on VWF [18] . Interestingly, although CLEC4M has been described as a mannose-binding lectin, glycomic analysis of human plasma-derived VWF identified predominantly complextype N-linked glycans with only trace evidence of a high mannose structure [28] . Although the majority of N-linked glycans on FVIII are also of complex type, the A1 (Asn-258) and C1 (Asn-2137) domains each contain a single high mannose glycan [27, 29, 30] . Here, the ability of CLEC4M to interact with N-and O-linked glycans on rFVIII was characterized. Removal of N-linked, O-linked, N-and O-linked, high mannose glycans and a(1-2,3,6)-linked mannose sugars was performed using endoglycosidase digestion as directed by the manufacturer (Sigma Aldrich or New England Biolabs, Ipswich, MA, USA) and confirmed by Galanthus nivalis lectin binding (Vector Labs, Burlingame, CA, USA) ( Figure S2 ). Removal of the rFVIII N-linked but not O-linked glycans attenuated binding to CLEC4M-Fc (Fig. 3A) . Removal of high (Fig. 3B) . CLEC4M-expressing cells were incubated with deglycosylated or control rFVIII for 2 h and FVIII:Ag in cell lysates was measured with ELISA. Removal of N-linked glycans, high mannose glycans or a(1-2,3,6) linked mannose sugars decreased internalization of rFVIII relative to controls (Fig. 3C) . Additionally, preincubation of CLEC4M-expressing cells with the mannose polymer mannan (100 lg mL
À1
) attenuated the binding/internalization of FVIII (Fig. 3D) .
CLEC4M internalizes VWF and FVIII through clathrin-coated pits
We have previously observed that VWF internalized by CLEC4M-expressing HEK 293 cells is transported to early endosomes [18] . To better characterize this endocytic pathway, CLEC4M-expressing cells were pretreated with methyl-b-cyclodextrin to deplete cell membrane cholesterol and disrupt lipid rafts, dynasore hydrate to inhibit dynamin GTPase activity, and pitstop-2, which binds the terminal domain of clathrin and prevents internalization of clathrin-coated pits. Cells were then incubated with human rFVIII or pdVWF-FVIII for 1 h and internalization was visualized by immunofluorescence ( Fig. 4A and B) . Internalized rFVIII or VWF was quantified by ImagePro analysis and demonstrated that binding/ internalization of rFVIII or pdVWF by CLEC4M-expressing cells was reduced by each of the three reagents used to disrupt the clathrin-coated pit-mediated endocytic pathway (Fig. 4A-D) .
To visualize the endocytic pathway of FVIII, CLEC4M-expressing HEK 293 cells were incubated with rFVIII for 15, 30 or 60 min [30] . When CLEC4M-expressing cells were exposed to rFVIII for 15 min, we observed colocalization between FVIII and early endosomal antigen 1 (EEA1), confirming that upon internalization by CLEC4M, FVIII is trafficked to early endosomes (Fig. 5A) . When CLEC4M-expressing cells were incubated with rFVIII for 30 min, we observed colocalization with Rab-9, a marker for late endosomes (Fig. 5B) . When CLEC4M-expressing cells were incubated with rFVIII for 1 h, we observed colocalization of FVIII with LAMP1, a lysosomal marker, suggesting that the internalization of FVIII by CLEC4M leads to lysosomal-mediated catabolism of the FVIII protein in this HEK 293-based model (Fig. 5C) . To confirm the role of lysosomes and proteasomes in the catabolism of FVIII, CLEC4M-expressing HEK 293 cells were incubated with rFVIII for 5 h, cells were washed, and then exposed to the lysosome inhibitors chloroquine disulfide (CLQ) and NH 4 Cl, and the proteasome inhibitor MG132 for 2 h. FVIII in cell lysates was measured by ELISA. Exposure of the cells to both the lysosomal inhibitors (CLQ and NH 4 Cl) and the proteasome inhibitor MG132 significantly increased detectable FVIII in the lysates of CLEC4M-expressing cells (Fig. 5D) .
We have previously demonstrated that VWF colocalizes with EEA1 post-internalization by CLEC4M-expressing cells [18] . Here we demonstrate that when CLEC4M-expressing cells were incubated with pdVWF-FVIII for 30 min, VWF colocalized with Rab-9 (Fig. 5E) . However, when CLEC4M-expressing cells were incubated with pdVWF-FVIII for 1 h, and in contrast to what we had seen with FVIII, we observed little colocalization of VWF with LAMP1 (Fig. 5F ).
Association of FVIII with CLEC4M-expressing cells in vivo
As mice do not express a CLEC4M ortholog, we have previously induced hepatic CLEC4M expression using hydrodynamic gene transfer [18] . Four days post-injection, mice with effective gene transfer had a 46% decrease in plasma levels of VWF:Ag. Plasma samples were then further characterized to examine endogenous levels of FVIII:C. In mice where 10-30% of hepatocytes expressed CLEC4M (as characterized by immunohistochemistry), plasma levels of FVIII:C were decreased compared with control mice that received hydrodynamic injections of the empty vector backbone (Fig. 6A ) (see Figure S3 for control experiments). ), is calcium dependent, partially reversible with a 500 mM NaCl wash, and competed with soluble plasma-derived VWF-FVIII complex (10 U mL À1 ) and recombinant FVIII (100 U mL À1 ). (E) Various soluble rFVIII products (full-length and B-domain deleted) (2 U mL À1 ) bound to immobilized CLEC4M-Fc (5 lg mL À1 ). FVIII binding was detected using a monoclonal anti-FVIII A1 antibody as We were unable to observe a change in endogenous plasma FVIII:C in VWF knockout (KO) mice that received hydrodynamic gene transfer of the CLEC4M cDNA compared with controls (data not shown). To demonstrate that CLEC4M-expressing cells can interact with human FVIII in vivo, we infused human rFVIII (10 lg) into VWF/FVIII DKO mice that had received a hydrodynamic gene transfer of the CLEC4M cDNA 4 days previously. Thirty minutes post-FVIII injection, the tissues were prepared for IHC and imaged using anti-human FVIII and anti-human CLEC4M antibodies. We observed that rFVIII was internalized by cells expressing CLEC4M as well as cells that did not express CLEC4M (Fig. 6B) . Finally, we demonstrate that LSECs, even in the absence of CLEC4M expression, are capable of endocytosing FVIII. FVIII KO or VWF-FVIII DKO mice were infused with human rFVIII as described, and FVIII localization with CD31-expressing LSECs was observed 30 min post-injection ( Fig. 6C and   D) . VWF/FVIII DKO mice were pretreated with cyclophosphamide to induce LSEC cytotoxicity. We observed an extended half-life of infused human rFVIII in the context of LSEC cytotoxicity (VWF/FVIII DKO mice t 1/2 = 17.03 min; cyclophosphamide-treated VWF/FVIII DKO mice = 25.79 min; P = 0.0075) (Fig. 6E) .
Discussion
VWF-bound FVIII has a prolonged half-life compared with VWF-free FVIII, and it is thought that the majority of VWF-bound FVIII is cleared by receptors that bind only to VWF, or to both VWF and FVIII, such as LRP1 (Low density lipoprotein receptor-related protein 1), stabilin-2 or SIGLEC5 (sialic acid-binding immunoglobulin-like lectin 5) [31] [32] [33] [34] . However, VWF-free FVIII has a short in vivo half-life, and up to~24% of plasma FVIII may be cleared by receptors capable of binding À1 ,1-h incubation) by CLEC4M-expressing cells preincubated with mannan (100 lg mL À1 ). For all assays, n = 3-5 independent experiments, AE SEM, *P < 0.05, **P < 0.001.
VWF-free FVIII, such as LRP1, SIGLEC5 and the asialoglycoprotein receptor ( Figure S4 ) [26, 33, [35] [36] [37] .
Although we have previously demonstrated that CLEC4M is a clearance receptor for VWF, here we extended this work to show that CLEC4M can regulate the binding, internalization and plasma levels of FVIII in both the absence and presence of VWF [18] . The N-linked glycans of FVIII have been shown to mediate interactions with the lectin receptors SIGLEC-5, the asialoglycoprotein receptor and the CLEC4M homolog DC-SIGN [33, 37, 38] , suggesting that glycans expressed on FVIII are important determinants of its in vivo half-life. In the absence of VWF, CLEC4M interacts with both the high mannose and complex type Nlinked glycans that are expressed throughout the FVIII molecule (Fig. 3) . Importantly, although glycosylation differences exist between plasma-derived and rFVIII preparations, including ABO blood group determinants, sialic acid content and occupancy of glycan sites, expression of high mannose glycans is relatively conserved and CLEC4M was able to interact with all FVIII products [27, 39] . To date, CLEC4M is the first mannose-binding lectin clearance receptor for FVIII, although high mannose glycans are involved in the recognition of FVIII by the mannose receptor (CD206) on dendritic cells and macrophages in vitro [40] . VWF and FVIII are among the first identified endogenous glycoprotein ligands for CLEC4M. Previous studies have characterized CLEC4M as an adhesive receptor capable of mediating viral infection in trans in an ICAM-3-dependent manner [17] and CLEC4M has not been previously shown to endocytose other proteins expressing high mannose glycans [41] . Thus, the mechanism by which CLEC4M internalizes VWF and FVIII, and the subsequent fate of these ligands, is uncharacterized. We observed that depletion of membrane cholesterol and inhibition of clathrin and dynamin GTPase activity impaired the endocytic activity of CLEC4M (Fig. 4) . This suggests that the CLEC4M receptor mediates endocytosis of its ligands through a clathrin-coated pit-dependent mechanism that involves lipid rafts. Consistent with these findings, microdomains of the CLEC4M-homolog DC-SIGN exist within lipid rafts, and depletion of membrane cholesterol attenuated binding and internalization of viral particles by DC-SIGN [42] .
Mice do not express a CLEC4M ortholog, and we have previously demonstrated that the CLEC4M murine homologue SIGNR1 (~55% amino acid identity), which is expressed on LSECs, does not modify VWF-FVIII plasma levels or half-life [34] . In this study we have demonstrated using a solid phase assay that CLEC4M is capable of binding to human rFVIII in the presence of defibrinated, recalcified normal human plasma (containing VWF) when compared to a BSA control (Fig. 2B) , suggesting that FVIII and CLEC4M interact in vivo. We have previously demonstrated that transgenic expression of CLEC4M by hepatocytes using hydrodynamic injection of the CLEC4M cDNA was associated with decreased plasma levels of VWF [18] . Here, we observed a decrease in endogenous FVIII in mice expressing CLEC4M on 10-30% of hepatocytes relative to mice that received the empty pLIVE vector via hydrodynamic injection (Fig. 6A) , suggesting that hepatic expression of CLEC4M can facilitate clearance of the endogenous murine VWF-FVIII complex. We further demonstrated that infused human rFVIII can associate with CD31-expressing LSECs in the liver of FVIII KO mice, where circulating murine VWF is present (Fig. 6C ). This suggests that even in the absence of CLEC4M expression, the pattern of blood flow and anatomical structure of the liver promote the association between FVIII and LSECs and is consistent with our previous observation that treatment of mice with cyclophosphamide, which is cytotoxic to sinusoidal endothelial cells, can increase plasma levels of endogenous FVIII in normal mice and prolong the half-life of human rFVIII in FVIII KO mice [34] . As CLEC4M can also directly interact with FVIII in the absence of VWF, we confirmed that this interaction can occur in recalcified, defibrinated VWF-deficient plasma when compared with a BSA control (Fig. 2B) . However, the quantitative influence of CLEC4M on FVIII plasma levels in vivo was more challenging to demonstrate in the absence of VWF, likely because of the short in vivo half-life of VWF-free FVIII and the variable and artificial expression of hepatic CLEC4M by hydrodynamic expression. We observed that infused rFVIII was associated with CLEC4M-expressing hepatocytes in our hydrodynamic gene transfer model (Fig. 6B) . However, as FVIII was also taken up by other cells in the liver, and the hepatocyte asialoglycoprotein receptor has been reported to bind VWF-free FVIII [25, 37, 43] , it is not possible to definitively state that hepatocyte uptake of FVIII in this model was mediated by CLEC4M. We did confirm, however, using VWF/FVIII DKO mice, that human rFVIII can be taken up by CD31-expressing LSECs, suggesting that these cells can contribute to the clearance of FVIII in the presence or absence of VWF. Although supraphysiological levels of rFVIII were utilized to facilitate FVIII detection in these imaging studies, these doses are similar to those employed in previous publications and are in line with the range of physiological antigen concentrations of other large plasma proteins such as VWF and fibrinogen [20, 44, 45] . Moreover, we demonstrate that infusion of therapeutic levels of human rFVIII (200 U kg
À1
) into VWF/FVIII DKO mice treated with the LSEC cytotoxic agent cyclophosphamide prolongs the half-life of FVIII in the absence of VWF (Fig. 6E) , confirming that LSEC-expressed endocytic pathways contribute to the clearance of VWF-free FVIII even in the absence of CLEC4M expression.
Together, these data suggest that CLEC4M, a previously characterized clearance receptor for VWF, can also bind and internalize human FVIII in both a VWF-dependent and independent manner. Elucidation of the mechanistic basis of VWF-independent FVIII clearance provides new information concerning quantitative trait loci influencing FVIII plasma levels and contributes insights into novel strategies for improving the half-life of FVIII replacement products. LSECs are recognized to be the cellular source for a substantial proportion of FVIII production [46] [47] [48] , as well as a location of VWF-FVIII clearance and catabolism, and are thus likely to be important regulators of plasma FVIII levels. Future studies on the interactions between VWF, FVIII and the sinusoidal endothelial cell secretory and clearance pathways, including those involving CLEC4M, are likely to yield novel insights into the FVIII life cycle. 
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